In October, due to demand from existing healthcare partners, CTS began testing blood donors for antibody to Babesia microti under an Investigational New Drug exemption as a release test.
Continue to meet or exceed healthcare partners’ expectations by providing on-time test results appr...
In July, the six viral marker assay conversion at CTS Dallas, Phoenix and Tampa laboratories was ach...
In August, the CTS Tampa lab transitioned to the same laboratory information systems (LIS) as the Da...
CTS embraces a company-wide operational excellence initiative designed to change the culture to enha...
In January, CTS is incorporated as a non-profit organization owned by Vitalant and OneBlood (formerl...
In 2016, CTS tested more source plasma samples (4.9 million) than blood donor samples (4.5 million).